The company expects to launch the Kit in July 2008. The Kit is designed to detect TMPRSS2 and ETS gene fusions in prostate pathological tissues.
Xiaodong Wu, chairman and CEO of China Medical Technologies, said: “The successful development of the Kit is a milestone in expanding our Fluorescent in situ Hybridization (FISH)reagent portfolio, which represents the first significant product developed by our researchers since the FISH acquisition in 2007.”